- Home
- VCEL vs IDYA Comparison
VCEL vs IDYA Comparison
Compare VCEL & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VCEL
- IDYA
- Stock Information
- Founded
- VCEL 1989
- IDYA 2015
- Country
- VCEL United States
- IDYA United States
- Employees
- VCEL N/A
- IDYA N/A
- Industry
- VCEL Biotechnology: Biological Products (No Diagnostic Substances)
- IDYA Biotechnology: Pharmaceutical Preparations
- Sector
- VCEL Health Care
- IDYA Health Care
- Exchange
- VCEL Nasdaq
- IDYA Nasdaq
- Market Cap
- VCEL 2.1B
- IDYA 1.9B
- IPO Year
- VCEL 1997
- IDYA 2019
- Fundamental
- Price
- VCEL $41.83
- IDYA $21.12
- Analyst Decision
- VCEL Strong Buy
- IDYA Strong Buy
- Analyst Count
- VCEL 8
- IDYA 13
- Target Price
- VCEL $62.00
- IDYA $53.42
- AVG Volume (30 Days)
- VCEL 430.3K
- IDYA 1.1M
- Earning Date
- VCEL 07-31-2025
- IDYA 08-05-2025
- Dividend Yield
- VCEL N/A
- IDYA N/A
- EPS Growth
- VCEL 521.85
- IDYA N/A
- EPS
- VCEL 0.05
- IDYA N/A
- Revenue
- VCEL $238,541,000.00
- IDYA $7,000,000.00
- Revenue This Year
- VCEL $23.03
- IDYA $101.20
- Revenue Next Year
- VCEL $24.52
- IDYA $286.70
- P/E Ratio
- VCEL $805.02
- IDYA N/A
- Revenue Growth
- VCEL 14.80
- IDYA N/A
- 52 Week Low
- VCEL $37.39
- IDYA $13.45
- 52 Week High
- VCEL $63.00
- IDYA $44.42
- Technical
- Relative Strength Index (RSI)
- VCEL 47.28
- IDYA 50.44
- Support Level
- VCEL $40.53
- IDYA $21.08
- Resistance Level
- VCEL $43.57
- IDYA $22.86
- Average True Range (ATR)
- VCEL 1.67
- IDYA 0.97
- MACD
- VCEL -0.10
- IDYA -0.22
- Stochastic Oscillator
- VCEL 27.68
- IDYA 25.51
About VCEL Vericel Corporation
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.
About IDYA IDEAYA Biosciences Inc.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.